Recombinant strains of herpes simplex virus-1 (HSV-1) harboring mutations in the infected cell product (ICP)34.5 region lose their neurovirulence and replicate more efficiently in dividing tumor cells than stationary cells, becoming replication-selective oncolytic agents. Additional mutation of the ICP6 gene, which encodes ribonucleotide reductase, further impairs the ability of HSV-1 mutants to replicate in normal cells, enhancing tumor selectivity. The present study investigated the effect of HSV-G207, a recombinant HSV-1 lacking ICP34.5 and ICP6, against epithelial ovarian cancer (EOC) in vitro and in vivo in a mouse xenograft model. To assess the selectivity of multimutated HSV-G207 against malignant cells, HSV-G207 and wild-type HSV-F were comparatively tested against normal human peritoneal mesothelial cells and EOC cells in vitro. HSV-G207 infected both EOC cells and mesothelial cells; however, unlike EOC cells, mesothelial cells provided a poor substrate for replication of HSV-G207. In contrast to wild-type HSV-F, HSV-G207 exerted a potent oncolytic effect on EOC cells but spared normal mesothelial cells in vitro. Primary EOC cells were more sensitive to the virus than established EOC cell lines. A single intraperitoneal injection of HSV-G207 resulted in a significant reduction in tumor volume and tumor spread in vivo. HSV-G207 was shown to penetrate deeply within tumor nodules and caused no apparent intraperitoneal toxicity. Oncolytic therapy with multimutated replication-restricted HSV may offer a novel approach in the treatment of EOC. Cancer Gene Therapy (2000) 7, 275-283 Key words: Viral oncolytic therapy; herpes simplex virus; ovarian cancer; intraperitoneal therapy. V iral-based oncolytic therapy has gained renewed interest due to recent advances in molecular virology allowing for manipulation of the viral particles and enhancement of their tumor specificity.
V iral-based oncolytic therapy has gained renewed interest due to recent advances in molecular virology allowing for manipulation of the viral particles and enhancement of their tumor specificity. 1, 2 Replicationselective herpes simplex virus-1 (HSV-1) mutants have been engineered by deletions of both copies of the RL1 gene. 3 Its product, infected cell product (ICP)34.5 protein, plays a major role in neurovirulence 4 and in prevention of the premature shutoff of protein synthesis in infected cells.
5 ICP34.5-null HSV-1 mutants such as HSV-1716 and HSV-R3616 have been shown to replicate preferentially in tumor cells, causing a direct oncolytic effect. 2, 6 HSV-G207 was further attenuated by inserting the Escherichia coli lacZ gene into the HSV ICP6 gene, which encodes ribonucleotide reductase (RR), on the ICP34.5
Ϫ backbone of HSV-R3616. 7 HSV-G207 was shown to be hypersensitive to the antiherpetic drug ganciclovir 7 and to display no detectable neurovirulence. 7, 8 Replication-selective HSV-1 mutants have been demonstrated to be efficacious antitumor agents in experimental models of various central nervous system (CNS) tumors. 3,4,8 -17 Based on promising preclinical results in experimental CNS tumors, dose escalation phase I clinical trials have begun using stereotactic application of HSV-G207 and HSV-1716 for the treatment of malignant tumors of glial origin (R. L. Martuza, personal communication; S. M. Brown, personal communication).
Based on the apparent efficacy of recombinant HSV-1 on CNS tumors, oncolytic therapy of extra-CNS malignancies with recombinant replication-restricted HSV-1 has emerged as a possibly appealing strategy, and several investigators have reported that conditionally replicative HSV-1 also exerts oncolytic activity against extra-CNS tissues. 18 We first demonstrated the efficacy of HSV-1716 against malignant intraperitoneal (i.p.) mesothelioma in a murine xenograft model. 19 A single i.p. administration of the virus led to significant tumor reduction and increased survival. More recently, the efficacy or tumor selectivity of recombinant HSV-1 was also shown in a subcutaneous melanoma, 20 breast carcinoma, 21 and colorectal carcinoma. 22 Because HSV-1 may infect various types of human tissues, the tumor selectivity of these agents becomes an important regulatory issue. The selectivity of mutant HSV-1 against malignant extra-CNS tissues has not been established yet. However, preliminary experiments with intracerebral inoculation of HSV-sensitive animals, such as the immunodeficient mouse or non-human primates, 8 indicate that application of G207 in the brain is safe. In the severe combined immunodeficient (SCID) mouse, no detectable toxicity was observed with i.p. administration of HSV-1716. 19 Moreover, no viral spread was detected outside the tumor by immunohistochemistry or polymerase chain reaction analysis of murine i.p. and retroperitoneal organs as well as distant organs, including the brain. By sharp contrast, administration of wild-type (wt) HSV-1 was followed by rapid viral spread and animal death within 1 week. 19 Furthermore, intrasplenic administration of a RR Ϫ HSV mutant resulted in selective infection of intrahepatic metastatic colon carcinoma cells but not of normal murine hepatocytes. 22 A possible extra-CNS application of recombinant HSV-1 is by direct intracavitary injection for the treatment of malignancies confined to body cavities. Advanced epithelial ovarian carcinoma (EOC) is characterized by localized i.p. growth rather than distant spread; therefore, it is an attractive candidate for i.p. approaches of treatment. 23 According to the National Cancer Institute's Surveillance, Epidemiology, and End Results program, Ͼ22,000 new cases of EOC are diagnosed annually in the United States, and Ͼ13,300 deaths occur from this disease. 24 Ovarian cancer has become the fourth most common cause of cancer death in women, ranking behind lung, breast, and colon cancer. Unfortunately, the 5-year survival rate still remains disappointingly low at 20 -30%, mainly due to the development of chemotherapy resistance. 25 Therefore, promising novel approaches to the treatment of advanced EOC warrant investigation. We recently provided evidence on the efficacy of an ICP34.5-deficient HSV-1 mutant against EOC in vitro and in vivo. A single i.p. administration of 5 ϫ 10 6 particle-forming units led to significant reduction of established i.p. disease and to significant prolongation of animal survival. 26 Application of recombinant HSV-1 via the i.p. route is technically feasible and becomes clinically attractive, but could potentially lead to significant intraabdominal toxicity, should the viral vectors display low specificity for malignant cells. In the present study, we sought to define the oncolytic activity of doubly deleted HSV-G207 against EOC. Moreover, to test the tumor specificity of the virus against tumor cells, we evaluated the cytotoxic activity of HSV-G207 against normal human peritoneal mesothelial cells, which cover the visceral and parietal surfaces of the entire abdominal cavity.
MATERIALS AND METHODS

Virus
Recombinant HSV-G207 was engineered on the ICP34.5 Ϫ backbone of HSV-R3616 by recombining the E. coli lacZ coding sequence into the ICP6 gene (UL39), a region encoding the large subunit of HSV RR.
7 G207 was generously provided by R. L. Martuza (Washington, DC). R. L. HSV-1(F) is a prototype wt backbone and was provided by NeuroVir (Vancouver, British Columbia, Canada).
Cells
The EOC cell lines SKOV3, NIH:OVCAR3, and CaOV3 were obtained from the American Type Culture Collection (Manassas, Va). The A2780 EOC line was a kind gift of Dr. Tom Hamilton (Fox Chase Cancer Center, Philadelphia, Penn). Primary ovarian cultures were obtained from malignant effusions of patients with stage III or IV EOC, according to the International Federation of Gynecologists and Obstetricians (FIGO). 27 EOC cells were cultured in RPMI 1640 media supplemented with 10% heat-inactivated fetal calf sera, 2 mM L-glutamine, and antibiotics at 37°C in a 5% CO 2 atmosphere. Primary EOC cultures had an epithelial-like phenotype and a rapid doubling time (average 18 hours) in vitro, and were passaged four to five times before being used in experiments. Normal peritoneal mesothelial cells were obtained from intraoperative normal saline peritoneal lavages carried out in patients undergoing laparotomy for benign pelvic pathology. Cells were cultured in the above media supplemented with a commercially available mixture of growth factors (SerXtend™, Irvine Scientific, Santa Ana, Calif) at a 0.1% dilution. Mesothelial cells also assumed an epithelial-like phenotype and grew in a cobblestone pattern. Their doubling time was 36 hours on average, and they propagated for only four to five passages, even in the presence of growth factors. Macrophages were removed from the primary cultures by replating the nonadherent cells into new culture flasks after a 30-minute incubation. Institutional Review Board approval was obtained for the retrieval and use of primary cultures.
Assessment of cytotoxicity in vitro
For dose-curve experiments, EOC cells were plated at a density of 3 ϫ 10 3 cells/well in 96-well plates. For 100% confluent cultures, cells were plated at a density of 20 ϫ 10 2:1 (vol/vol) at Ϫ20°C for 20 minutes. A polyclonal rabbit antibody (Ab) against HSV-1 (American Qualex, La Mirada, Calif) was used at 1:250 in 10% goat sera. A fluoresceinconjugated goat anti-rabbit secondary Ab (Jackson Immunoresearch Laboratories, West Groove, Penn) was used at 1:250.
Flow cytometry analysis of HSV antigens (Ags)
Cells were cultured in T25 flasks until they reached 60% confluence. They were then infected with 1 MOI of HSV-G207, as described above. Cells were harvested at 16 hours with a 0.05% trypsin solution, fixed/permeabilized as described above, incubated with the same Abs as above, and subjected to flow cytometry.
Viral burst assays
Cells were plated in 6-well plates at a density of 4 ϫ 10 5 cells/well in appropriate media overnight and subsequently infected with HSV-G207 at an MOI of 0.3 for 1 hour. Cells were harvested in their media by mechanical scraping after exposure to the virus for 0, 6, 19, and 24 hours postinfection, and lysates were immediately stored at Ϫ80°C. Black plaque assays were carried out to measure the titer of the virus at each timepoint. Viral burst size was calculated as the ratio of the number of plaques on baby hamster kidney (BHK-21) cells infected with lysates from 24 hours divided by the number of plaques on BHK cells infected with lysates from 0 hours as described previously. 19 
In vivo treatment of EOC with HSV-G207
Female CB17 SCID mice (Charles River, Wilmington, Mass) of 6 to 8 weeks of age were housed in isolation units and were cared for according to the Animal Use Committees of the Wistar Institute and the University of Pennsylvania, in compliance with National Institutes of Health Publication 85-23, revised 1985. SKOV3 cells (5 ϫ 10 6 cells/animal) suspended in 0.5 mL of RPMI 1640 media containing 10% fetal calf sera and 1% SerXtend™ (Irvine Scientific) were injected i.p. into SCID mice. A group of mice (n ϭ 5) was sacrificed at 2 weeks to assess the amount of i.p. tumor. At that time, a group of animals (n ϭ 10) received a single i.p. dose of HSV-G207 at 5 ϫ 10 6 plaque-forming units in 500 L of RPMI 1640 serum-free media. (A similar dose of HSV-1716 was found to be safe and effective in our previous studies with mesothelioma and EOC.) 19, 26 A group of control animals (n ϭ 10) received a similar volume of nonsupplemented media.
A semiquantitative scoring system was developed to grade tumor spread on a scale of 0 -3 as follows: "0" if no microscopic tumor was seen; "1" if microscopic tumor was visible with the aid of a dissecting microscope at ϫ2.5 magnification; "2" if tumor nodules Ͻ5 mm were visible; and "3" if tumor nodules Ն5 mm (as measured by calipers) were present. Two independent investigators, which were blinded to the treatment groups, conducted the scoring. The following five areas were screened for the presence of tumor: (a) the injection site, (b) the parietal peritoneum and diaphragm, (c) the small bowel mesentery and omentum, (d) the lesser omentum and hepatic hilum; and (e) the retroperitoneum. The presence of ascites added one additional point in the scoring system; therefore the maximum score was 16. All visible nodules of tumor were recorded and then dissected from surrounding normal peritoneum and viscera. The total intra-abdominal tumor was weighed for each animal individually.
Histology and immunohistochemistry
Tumor nodules, harvested from treated and control animals, were fixed immediately in formalin and embedded in paraffin. Six-micron thick sections were stained with hematoxylin-eosin for histology. For immunohistochemistry, slides were subjected to Ag retrieval at 105°C for 10 minutes in 0.1N citric acid and incubated with a monoclonal Ab against HSV-1 (Dako, Carpenteria, Calif) at a dilution of 1/4 for 30 minutes at 47°C and a horseradish peroxidase-conjugated anti-mouse Ab (1/400 dilution; Vectastain, Vector Laboratories, Burlingame, Calif). Slides were processed using the avidin-biotin complex kit (Vector Laboratories). Negative controls included an isotypematched mouse monoclonal Ab diluted 1/4 (Dako).
Statistical analysis
Statistical analysis was computed using multiple comparisons of a one-way analysis of variance. Post-hoc comparisons of specific paired groups were performed using the Student t test. Statistical significance was set at P Ͻ .05. Results are expressed as the mean Ϯ SE (M Ϯ SE).
RESULTS
HSV-G207 infects and exerts a dose-dependent oncolytic effect on EOC in vitro
The oncolytic effect of G207 was assessed on primary EOC cultures and established EOC cell lines in vitro. G207 exerted a direct dose-dependent cytolytic effect on all EOC cell lines (Fig 1A) . Primary EOC cultures displayed 10-to 30-fold higher sensitivity compared with established EOC cell lines. Primary EOC cells and established EOC cell lines exhibited CPEs such as cell rounding, fragmentation, or giant cell formation within 48 -72 hours at 1 MOI. An example of a CPE is provided in Figure 1B , where most of the SKOV3 cells displayed CPEs at 72 hours. To assess the magnitude of infection by HSV-G207, HSV immunofluorescence was carried out on SKOV3 cells at 72 hours after exposure to HSV-G207, indicating that Ͼ98% of the cells were expressing HSV Ag at that time (Fig 1C) .
HSV-G207 infects but exerts a minimal cytotoxic effect on normal human mesothelial cells in vitro
To compare the susceptibility of primary mesothelial peritoneal cells, primary EOC cells, and established EOC cells (SKOV3) to infection by HSV-G207, we first performed flow cytometry. After exposure to 1 MOI of HSV-G207 for 16 hours, a significantly lower percentage of peritoneal mesothelial cells was infected (54.6 Ϯ 9%; P Ͻ .05 versus SKOV3 or primary EOC) compared with SKOV3 (71.8 Ϯ 10%) or primary EOC cells (74.5 Ϯ 7%; P ϭ 1.12 versus SKOV3) (Fig 2A) . However, after incubation for 48 hours, ϳ99% of the cells were infected from all cell types (data not shown).
To investigate the tumor specificity of HSV-G207, we assessed the effect of HSV-G207 comparatively on primary mesothelial peritoneal cells, primary EOC cells, and established EOC cells (SKOV3) in vitro. Moreover, to assess the impact that the attenuation of HSV-G207 has on the killing effect of the virus, primary mesothelial peritoneal cells, primary EOC cells, and SKOV3 cells were exposed to wt HSV-F in parallel experiments. Mesothelial cells promptly underwent growth arrest in vitro under confluent conditions, due to contact inhibition (data not shown). The EOC cell line SKOV3 also appeared to undergo growth arrest at 100% confluence, whereas primary EOC cells did not. Because the oncolytic effect of ICP34.5-deleted HSV is more potent on rapidly replicating cells, 28 we performed experiments both under confluent and nonconfluent conditions.
HSV-G207 exerted a potent dose-dependent oncolytic effect on primary EOC cells that was similar under nonconfluent and confluent conditions (Fig 2B) . HSV-G207 also exerted a potent oncolytic effect on SKOV3 cells, but was significantly more efficient in lysing rapidly proliferating SKOV3 cells than confluent SKOV3 cells (P Ͻ .05 for MOIs of 0.1 and 1). However, HSV-G207 exerted no apparent cytotoxicity against normal mesothelial cells plated at 10% confluence at lower concentrations, such as 0.01 and 0.1 MOI, but displayed a mild cytotoxic effect at 1 MOI (P Ͻ .05 versus MOIs of 0, 0.01, and 0.1). Most importantly, HSV-G207 exhibited no apparent cytotoxicity on confluent mesothelial cells at MOIs of 0.01 and 0.1, and exerted an even milder oncolytic effect at 1 MOI compared with nonconfluent cells (P Ͻ .05 versus MOIs of 0, 0.01, and 0.1) (Fig 2B) . There was a significant difference between the cytotoxicity of HSV-G207 on confluent and nonconfluent mesothelial cells at 1 MOI (P Ͻ .05). However, HSV-F exerted a clear dose-dependent cytotoxic effect against primary EOC cells, SKOV3 cells, and normal mesothelial cells, independently of the state of confluence ( Fig  2C) . There were no significant differences with regard to the effect of HSV-F among the primary mesothelial cells, the primary EOC cells, or SKOV3 cells. Moreover, there were no significant differences in the effect of HSV-F on the different cell types between the two culture conditions.
Normal human mesothelial cells are less permissive than EOC cells for replication of HSV-G207
The oncolytic efficacy of replication-restricted HSV-1 may directly depend upon its ability to replicate within the target cells. 2, 6 To compare the ability of normal human mesothelial cells and established EOC cell lines to support the replication of HSV-G207, we measured the viral burst size in these cells. A significantly lower burst size was observed in the two mesothelial primary cultures tested (3 Ϯ 1 and 4 Ϯ 1, respectively) compared with SKOV3 cells (8 Ϯ 2, P Ͻ .01) and A2780 cells (23.5 Ϯ 3, P Ͻ .01) ( Table 1) .
HSV-G207 penetrates within tumor nodules and exerts an oncolytic effect on EOC in vivo with no toxicity The efficacy of HSV-G207 in treating established i.p. EOC was assessed in a murine xenograft model using the well-characterized EOC cell line SKOV3. An i.p. injection of 5 ϫ 10 6 SKOV3 cells resulted in microscopic tumor at the diaphragm and occasionally the omentum, mesentery, or lesser omentum within 2 weeks (tumor weight: 13 Ϯ 7 mg; tumor score: 3.8 Ϯ 0.06; n ϭ 5). At that time, animals received a single i.p. injection of HSV-G207 (n ϭ 10) or medium (n ϭ 10). At 3 weeks posttreatment, animals that received virus displayed significantly smaller tumors (55 Ϯ 6 mg) compared with control animals (265 Ϯ 18 mg; P Ͻ .001) (Fig 3A) . Moreover, tumor spread was significantly lower in treated animals (tumor score: 5.8 Ϯ 0.5) compared with controls (tumor score: 15 Ϯ 0.6, P Ͻ .01) (Fig 3B) . Animals tolerated the treatment well, and there were no deaths.
Treated animals displayed intense immunostaining for HSV within multiple tumor nodules (Fig 4A) . Scattered infected areas were noted within tumor nodules stained with the Ab against HSV-1 (Fig 4B) , whereas no staining was detected in tumors stained with preimmune sera (negative control, Fig 4C) . Areas of tissue necrosis were adjacent to areas in which cells were infected by HSV Cells were infected with HSV-G207 at an MOI of 0.3. Viral burst size was calculated using a black plaque assay as described previously. 21 A significantly lower burst size was observed in the two mesothelial primary cultures tested compared with SKOV3 and A2780 cells ‫,ء(‬ P Ͻ .01 compared with both ovarian cancer cells). ( Fig 4D) . Consistent with previous observations in SCID mice treated with HSV-1716, 19, 26 no HSV-1 staining was detected in normal murine tissues, including the peritoneal surfaces (data not shown). To assess the degree of i.p. toxicity after i.p. administration of HSV-G207, sections of i.p. organs were evaluated histologically. No inflammation was detected in the viscera of treated animals ( Fig 4E) . Moreover, there was no evidence of i.p. adhesion formation in treated or control animals (Fig 4, F and G) .
DISCUSSION
Advanced EOC remains localized within the peritoneal cavity in a large portion of patients and may be amenable to i.p. oncolytic therapy. We hypothesized that i.p. administration of HSV-G207, a recombinant HSV-1 with attenuated virulence, may be efficacious in the treatment of EOC. To test this hypothesis, the susceptibility of EOC cells to infection by HSV-G207 was first assessed in vitro. By immunofluorescence and flow cytometry, we demonstrated that the virus efficiently infects EOC cells, suggesting that EOC cells possess cell surface receptors allowing for HSV entry. EOC cells were killed in a dose-dependent manner by HSV-G207. It was interesting to note that the primary EOC cultures appeared to be ϳ10-to 30-fold more sensitive to G207 than the established EOC cell lines, yet they became infected by the virus at the same rate. These results are in agreement with previous evidence from our laboratory that EOC cells from both established cell lines and primary cultures are sensitive to the oncolytic effect of ICP34.5-deleted HSV-1716 mutant. 26 The mechanisms underlying the differences observed between primary and established EOC lines were beyond the aims of this study. It is possible that mutations accumulated in vitro might affect the magnitude of viral replication or the susceptibility of the cells to HSV-induced cell killing. This is not always the case between primary cultures and established lines. For example, primary glioblastoma multiforme cultures displayed a similar sensitivity to a mutated HSV-1 agent 6 as established glioma cell lines. The efficacy of HSV-G207 in vivo was tested in a xenograft SCID model using the established SKOV3 EOC cell line, which displayed the least susceptibility to HSV-induced killing in vitro. A single i.p. administration of HSV-G207 to tumor-bearing animals resulted in a significant reduction in tumor growth and in a limitation of tumor spread within the peritoneal cavity 3 weeks later. These results are in agreement with previous evidence that ICP34.5-deleted mutant HSV-1716 was efficacious against EOC in vivo in mice bearing SKOV3 as well as A2780 tumors. 26 Our immunohistochemistry studies showed that the virus was localized deeply into the tumor tissue after i.p. delivery. Although the possibility that the tumor grew around infected areas that previously were located on the surface of tumor nodules cannot be excluded, it is possible that viral replication within the tumor led to viral spread and penetration deep in the tumor nodules. Toda et al 21 demonstrated previously that intratumoral injection of HSV-G207 within subcutaneous nodules of breast carcinoma resulted in intratumoral spread of the virus. The present data provide the first evidence that diffuse i.p. administration of HSV-G207 results in similar intratumoral spread of the virus. Despite evidence that HSV-G207 spread within the tumor and exerted an oncolytic effect, complete cures were not observed. Based on the doserelated response observed in vitro, the outcome in vivo would be dependent upon the growth rate of the tumor and the sensitivity of the tumor cells to the HSV mutant. It may be hypothesized that the dose of virus administered i.p was insufficient to replicate and spread rapidly enough to completely lyse the tumor, which instead outgrew the effect of the virus. Another possibility is that HSV-G207 may not have efficiently lysed the nonproliferating portions of the SKOV3 tumor nodules, as seen in vitro, where growth-arrested cells displayed lower sensitivity to HSV-G207. Based on our observation that primary EOC cultures displayed a higher sensitivity to G207 in vitro, a higher efficacy of the virus may be anticipated against primary EOC tumors in vivo.
Several approaches are being undertaken to augment the antitumoral effect of HSV-based oncolytic agents in various laboratories. Andreansky et al 11 and Toda et al 29 have shown that coexpression of interleukin-4 or interleukin-12 can augment the efficacy of HSV-based oncolytic therapy for the treatment of gliomas or colorectal carcinoma, respectively. Advani et al 30 have shown that adjuvant radiation therapy can augment the efficacy of HSV-R3616 oncolytic therapy. We are pursuing a cell carrier system to augment the delivery of HSV mutants to tumors, thereby increasing the effective dose. 26 It is of interest in the present study that the extent of viral spread observed by immunohistochemistry did not match the magnitude of tumor reduction observed. Although it is possible that HSV Ags might have degraded sufficiently so as to be undetected by the anti-HSV Ab used, an alternate interpretation is that part of the antitumoral effect of HSV-G207 may have been caused by mechanisms other than direct cell infection. Recently, Brandt et al 31 reported that the antitumoral effect of a recombinant attenuated HSV-1/HSV-2 strain was much greater than the viral distribution in the tumor. HSV-infected cells are known to release cytokines, 32 which are possible mediators of bystander effects. 33 Interestingly, wt HSV-1 was reported to induce apoptosis in adjacent cells both in vitro and in vivo. 34, 35 It is possible that HSV-induced bystander killing mechanisms may augment the oncolytic effects of HSV-1 mutants.
HSV-1 mutants lacking ICP34.5 preferentially replicate in proliferating cells, gaining specificity toward proliferating malignant cells.
1,2 RR is a distinct HSVencoded gene involved in viral DNA synthesis, which is indispensable for viral replication in nondividing cells. 36 RR is also expressed by eukaryotic cells, but is upregulated in a cell-cycle-dependent manner. In fact, RR is implicated in the control of DNA synthesis. 37 The loss of RR was anticipated to further abrogate the ability of HSV ICP34.5
Ϫ virus mutants to replicate in normal quiescent cells, 38 which lack expression of endogenous RR. 37 As a result, the tumor specificity profile of RR Ϫ viruses would be significantly enhanced. 15 Fulfilling the expectations, HSV-G207 has been shown to exhibit minimal toxicity in the experimental treatment of various CNS and extra-CNS tumors. Ongoing phase I clinical trials of stereotactic intra-CNS injections of HSV-G207 for the treatment of malignant tumors of glial origin will be forthcoming on the safety profile of this agent in humans (R. L. Martuza, personal communication; S. M. Brown, personal communication).
Extra-CNS applications of attenuated HSV-1 raise special toxicity issues. For instance, in the case of EOC, a likely therapeutic approach may be direct i.p. injection of the virus. If the virus is not selective enough, it might result in viral peritonitis and severe inflammation. In the immunocompetent human, despite the high prevalence of lower genital tract herpetic infections, herpetic peritonitis is virtually unknown. 39 This might suggest that mesothelial cells are not susceptible to HSV infection. In the present study, however, we found that mesothelial cells are susceptible to infection by HSV, albeit to a lesser extent than EOC cells. In fact, nonattenuated wt HSV-F caused rapid destruction of mesothelial cells in vitro, in manner similar to EOC cells. In contrast, multi-attenuated HSV-G207 exerted significantly less toxicity on monolayers of normal human peritoneal mesothelial cells compared with malignant EOC cells. This effect was even more pronounced on growtharrested mesothelial monolayers. One possible explanation for the tumor specificity of HSV-G207 is provided by the analysis of HSV-G207 replication in vitro in the different cells. We demonstrate that normal mesothelial cells provided a very poor substrate for HSV-G207 replication, likely accounting for the inability of HSV-G207 to rapidly kill these cells. A putative factor that might influence the magnitude of viral replication within the different cell types is RR. Endogenous cellular RR is a key enzyme in DNA synthesis both in HSV and in mammalian cells. Cellular RR can therefore complement the ICP6 deletion in HSV-G207 and enhance viral replication and cell killing. 38 Its cytoplasmic levels are regulated during the cell cycle in mammalian cells: the R1 subunit is absent in quiescent normal cells in G 0 phase and is newly acquired during transition to G 1 phase, 40 whereas the R2 subunit is up-regulated in S phase. 37 During the cell cycle, the enzyme levels markedly increase during the S phase. 37 As a result, levels of both subunits are abundant in normal proliferating cells but absent in quiescent diploid cells. In both normal and malignant cells, levels of RR were found to correlate with markers of proliferation such as Ki-67 and proliferating cell nuclear Ag. 41 In cervical carcinoma cells, for example, the cytoplasmic levels of the R2 catalytic subunit of RR increased 17-fold as cells entered S phase compared with quiescent cells in G 2 -M phase. 42 However, in sharp contrast to normal cells, malignant cells were shown to express high levels of RR in vivo and in vitro even in a quiescent state, possibly as a result of being arrested in G 1 phase, where RR is expressed. 43 Recent evidence indicates that malignant transformation is associated with markedly increased levels of RR independent of the cell cycle and DNA synthesis, due to aberrant regulation by a protein kinase C/transforming growth factor-␤ pathway. 44 Together with the observation that RR may be directly implicated in oncogenesis, 45 this finding suggests that malignant cells possess high constitutive levels of RR. These observations support our findings that growth-arrested mesothelial cells were relatively insensitive to the killing effect of HSV-G207, while the virus exerted a potent oncolytic activity against proliferating EOC cells and maintained activity against growth-arrested EOC cells.
Complementing the evidence that multi-attenuated HSV-G207 may not disrupt normal mesothelium, we did not observe any i.p. toxicity or inflammation caused by HSV-G207 in our xenogeneic EOC model. Furthermore, no HSV staining could be demonstrated in the mesothelial layer lining the peritoneal surfaces, in agreement with previous evidence. 19, 26 Previous studies have demonstrated that HSV-1716 lacking only ICP34.5 is avirulent in the SCID mouse, spreading only within tumor tissue, whereas wt HSV-1 rapidly spreads and kills the animals. 19 Taken together, these data suggest that mutant HSV-1 lacking ICP34.5 may be safe for i.p. administration. HSV-G207 is even further attenuated, yet maintains oncolytic efficacy against ovarian cancer cells. Further manipulation of ICP34.5 Ϫ HSV may yield oncolytic agents that display no toxicity to normal cells such as mesothelial cells.
In conclusion, the present study demonstrates that EOC is sensitive to attenuated recombinant HSV-G207 bearing a double mutation of ICP34.5 gene and ICP6 gene encoding RR. A single i.p. administration of the virus led to decreased tumor burden in vivo. In addition, HSV-G207 exerted significantly less cytotoxicity against normal human peritoneal mesothelial cells compared with malignant EOC cells and caused no i.p. toxicity in the animals. HSV-G207 may offer a novel approach for the treatment of EOC. Further studies to investigate the efficacy and safety of HSV-based oncolytic therapy for EOC are clearly warranted.
